Preprint Article Version 1 This version is not peer-reviewed

Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients during Two Years: Experience of One Center

Carmen Botella
,
Victor Jimenez-Coll
,
Marina Fernandez
,
Jose A Galian
,
Francisco Morales
,
Gloria Martínez-Gómez
,
Maria J Alegria
,
Rosana Gonzalez-Lopez
,
Maria R Moya-Quiles
,
Helios Martínez-Banaclocha
,
Alfredo Minguela
,
Isabel Legaz
,
Santiago Llorente
,
Manuel Muro
*
Version 1 : Received: 4 July 2024 / Approved: 4 July 2024 / Online: 5 July 2024 (13:44:14 CEST)

How to cite: Botella, C.; Jimenez-Coll, V.; Fernandez, M.; Galian, J. A.; Morales, F.; Martínez-Gómez, G.; Alegria, M. J.; Gonzalez-Lopez, R.; Moya-Quiles, M. R.; Martínez-Banaclocha, H.; Minguela, A.; Legaz, I.; Llorente, S.; Muro, M. Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients during Two Years: Experience of One Center. Preprints 2024, 2024070492. https://doi.org/10.20944/preprints202407.0492.v1 Botella, C.; Jimenez-Coll, V.; Fernandez, M.; Galian, J. A.; Morales, F.; Martínez-Gómez, G.; Alegria, M. J.; Gonzalez-Lopez, R.; Moya-Quiles, M. R.; Martínez-Banaclocha, H.; Minguela, A.; Legaz, I.; Llorente, S.; Muro, M. Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients during Two Years: Experience of One Center. Preprints 2024, 2024070492. https://doi.org/10.20944/preprints202407.0492.v1

Abstract

(1) Background: donor-derived circulating free DNA (dd-cfDNA) is an innovative biomarker with great potential for the early identification and prevention of graft damage; (2) Methods: Prospective study to analyze dd-cfDNA plasma levels in 30 kidney transplant patients during their post-transplant follow-up (15 days, 3, 6 and 9 months), to determine if the result could be of interest in the identification of possible adverse events, specially allograft rejection. In addition, the aim is also to verify the obtained data on sensitivity, specificity, NPV and PPV; (3) Results: Plasma levels of dd-cfDNA could be considered a novel biomarker of graft rejection after first term post-transplant up to several months before its clinical presentation, mainly in TCMR or ABMR. In this study, it appears to have no positive predictive value for borderline rejection or TCMR IA. Our results show a low NPV of the technique because other pathologies or biological post-transplant complications can also affect dd-cfDNA levels and they must be considered in the interpretation of the result.; (4) Conclusions: dd cfDNA could allow, together with other additional biomarkers in the context of a future score, avoid invasive biopsies in most cases, mainly in the case of suspected TCMR or ABMR.

Keywords

donor-derived circulating free DNA (dd-cfDNA); kidney transplant; graft rejection; biomarker; Non Rejection (NR), antibody-mediated rejection (ABMR); borderline rejection (BR); T cell mediated rejection (TCMR)

Subject

Medicine and Pharmacology, Clinical Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.